Dapagliflozin Enhances Arterial and Venous Compliance During Exercise in Heart Failure With Preserved Ejection Fraction: Insights From the CAMEO-DAPA Trial
Authors
Michael D. Jensen (ORCID: https://orcid.org/0000-0001-5589-8389)
Julio A. Chirinos (ORCID: https://orcid.org/0000-0001-9035-5670)
Dapagliflozin Enhances Arterial and Venous Compliance During Exercise in Heart Failure With Preserved Ejection Fraction: Insights From the CAMEO-DAPA Trial
Michael D. Jensen, Julio A. Chirinos, Bianca Pourmussa, Ryan T. Demmer et al.
Citations
33 citations
Journal
Circulation
Topics
Cardiovascular Function and Risk Factors
Field-Weighted Citation Impact (FWCI)
13.27
article
Dapagliflozin Enhances Arterial and Venous Compliance During Exercise in Heart Failure With Preserved Ejection Fraction: Insights From the CAMEO-DAPA Trial
Michael D. Jensen, Julio A. Chirinos, Bianca Pourmussa, Ryan T. Demmer, Jeffrey Moore Testani, Rickey E. Carter, Jwan A. Naser, Barry A. Borlaug, Yogesh N.V. Reddy, Daniel Burkhoff, Tomonari Harada, Atsushi Tada
article en
33 citations
Abstract
No abstract available for this paper.
Publication Tag
CirculationVol. 150(13)
Institutions
Yale New Haven Hospital (US), Mayo Clinic (US), Hospital of the University of Pennsylvania (US), Yale Cancer Center (US), Yale University (US), Mayo Clinic in Arizona (US), Cardiovascular Research Foundation (US), Mayo Clinic in Florida (US)